7月2日，福泰制药盘中上涨3.25%，报516.04美元/股，成交额8953.56万美元。
消息面上，美国FDA批准福泰制药基因疗法Casgevy扩大适用人群，将最低适用年龄从12岁降至2岁，覆盖镰状细胞病伴复发性血管闭塞危象及输血依赖型β地中海贫血患儿。公司表示，此次标签扩展预计使美国约5500名额外儿童患者有资格接受这一一次性细胞疗法治疗。此前6月公布的三期临床数据显示，5至11岁患儿接受Casgevy治疗后，所有患者均未再发生血管闭塞危象，输血依赖型患者也实现了连续12个月以上的输血独立。目前英国及沙特阿拉伯的标签扩展审评亦在进行中。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.